CEO sold ~$17K of Ovid Therapeutics
Automatic saleLoading…
OVID · NASDAQ · Pharmaceutical Preparations
Pharmaceutical Preparations company based in New York, Ny.
In the last 90 days, no insider of Ovid Therapeutics reported an open-market purchase and 0 open-market sales. Every figure links to its official SEC, House, Senate or USAspending record.
Revenue
$733K
−88.3% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $11.3M, at Jun 30, 2026
Net income, last 12 months
−$34.5M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Mar 18, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
None
No open-market sales reported
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$7.25M
+1181.3% vs the year before
Net income, fiscal 2025
−$17.4M
A loss for the year
Shares outstanding
195M
As of Aug 11, 2026
CEO sold ~$17K of Ovid Therapeutics
Automatic saleOfficer sold ~$12K of Ovid Therapeutics
Automatic salePrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Top officer leaving
“Rona’s departure, the Company’s Board of Directors (the “Board”) appointed Charles Carter, the Company’s Senior Vice President of Finance and Financial Planning, as the Company’s Chief Financial Officer, principal financial officer, principal accounting officer and secretary, effective as of the Separation Date.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.